{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-214740","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2021-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.105376+00:00","generated_at":"2026-06-30T05:26:41.313644+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M","bullets":["Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.","Net proceeds expected to be ~$46.8M after underwriting discounts and offering expenses.","Underwriters granted 30-day option to purchase up to 1,249,999 additional shares ($7.5M).","Closing expected July 16, 2021; Morgan Stanley, SVB Leerink, and Cantor are joint book-runners.","Company is a clinical-stage biotech focused on rare hemoglobin disorders; proceeds for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-214740","json":"https://secwatch.observer/filing/0001193125-21-214740.json","markdown":"https://secwatch.observer/filing/0001193125-21-214740.md","text":"https://secwatch.observer/filing/0001193125-21-214740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/0001193125-21-214740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/d138853d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T05:26:41.313644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}